Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Brest – page 29

584 clinical trials in Brest, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Brest at a glance
584
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

584 trials in Brest

Open in trial search

Pneumonia

Not yet recruiting

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Acute lymphocytic leukaemia

Not yet recruiting

Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pegaspargase
  • Sponsor:Assistance Publique Hopitaux De Paris

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Chronic kidney disease+1

Not recruiting

A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Bayer AG

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Muscle spasticity

Not recruiting

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Brest

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck squamous cell carcinoma, exploring innovative treatments combining radiotherapy with targeted therapies. Studies also examine new approaches for esophageal cancer and pancreatic adenocarcinoma.

  • Advanced Cancer Therapies
  • Combination Treatments
  • Targeted Therapeutics

Multiple trials are investigating novel drug combinations and immunotherapy approaches for various cancer types.

02 Autoimmune Conditions

Comprehensive research into Sjögren's syndrome treatment options, including innovative biological therapies and histopathological studies. Additional focus on rheumatoid arthritis and novel therapeutic approaches.

  • Biological Treatments
  • Disease Mechanisms
  • Treatment Response

Studies aim to understand disease mechanisms and evaluate new therapeutic options for autoimmune disorders.

03 Cardiovascular and Respiratory Studies

Investigation of treatments for pulmonary arterial hypertension and heart failure prevention. Research includes innovative drug combinations and preventive approaches for cardiovascular conditions.

  • Heart Failure Prevention
  • Hypertension Management
  • Asthma Control

Focus on developing effective treatments for chronic cardiovascular and respiratory conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.